论文部分内容阅读
目的:观察扶肝通利方联合西药治疗肝硬化顽固性腹水的疗效及安全性。方法:将肝硬化顽固性腹水患者124例作为研究对象,随机分为观察和对照两组,对照组采用西药治疗,观察组在对照组基础上联合中药自拟扶肝通利方进行治疗,连续治疗1个月后观察疗效。结果:对照组总有效率80.6%明显低于观察组96.8%,且差异具有统计学意义(P<0.05);观察组不良反应发生仅3例,不良反应发生率为4.8%,与对照组的17.7%比较,差异显著(P<0.05);对两组患者满意率进行比较,观察组也明显优于对照组,且具有显著差异(P<0.05)。结论:肝硬化顽固性腹水运用扶肝通利方联合西药进行治疗效果显著,安全性好,患者满意率高,应用于临床能够提高患者的生活质量,适合推广应用。
Objective: To observe the efficacy and safety of Fugan Tongli Decoction combined with western medicine in treatment of refractory cirrhosis and ascites. Methods: A total of 124 patients with cirrhosis and refractory ascites were randomly divided into observation and control groups. The control group was treated with western medicine. The observation group was treated with Fufang Tonglifang, After 1 month of treatment, the curative effect was observed. Results: The total effective rate was 80.6% in the control group was significantly lower than 96.8% in the observation group, and the difference was statistically significant (P <0.05); only 3 cases of adverse reactions in the observation group, the incidence of adverse reactions was 4.8% 17.7%, the difference was significant (P <0.05). Compared with the satisfaction rate of the two groups, the observation group was also significantly better than the control group, and there was significant difference (P <0.05). Conclusion: The treatment of refractory ascites due to liver cirrhosis with Fugan Tonglixifang combined with Western medicine has significant effect, good safety and high patient satisfaction. It can be used clinically to improve the quality of life of patients and is suitable for popularization and application.